BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Calendar//CN-US Event Research//ZH
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Calendar
X-WR-CALDESC:Market-moving event research, reminders and post-event review.
BEGIN:VEVENT
UID:evt-lilly-novo-q2-2026-obesity-earnings-window@catalyst-calendar.local
DTSTAMP:20260720T200648Z
DTSTART:20260805T140000Z
DTEND:20260805T153000Z
SUMMARY:Eli Lilly Q2 2026财报与GLP-1/代谢管线指引窗口
DESCRIPTION:Eli Lilly将于2026年8月5日举行Q2 2026 earnings call；公司市值和GLP-1/肥胖药物地位使其收入、供给、价格、口服GLP-1和retatrutide管线更新具有医药生物和消费医疗跨行业定价影响。\\nImpact score: 66\\nExpected: Q2收入、全年指引、GLP-1供给/价格、口服GLP-1商业化和下一代肥胖管线进度更新。\\nAffected: LLY(subject\, mixed\, score 88)\; NVO(subject\, mixed\, score 84)\; IBB(etf\, mixed\, score 60)\; VKTX(peer\, mixed\, score 58)\; AMGN(peer\, mixed\, score 54)\; HIMS(customer\, mixed\, score 38)\\nSources: Eli Lilly investor upcoming events: https://investor.lilly.com/\\nNovo Nordisk financial results overview: https://www.novonordisk.com/investors/financial-results.html\\nEli Lilly Q1 2026 results: https://investor.lilly.com/news-releases/news-release-details/lilly-reports-first-quarter-2026-financial-results-raises-full\\nEli Lilly webcasts and presentations: https://investor.lilly.com/webcasts-and-presentations\\nInformation only. Not investment advice.
URL:https://0.0.0.0:3000/?event=evt-lilly-novo-q2-2026-obesity-earnings-window
CATEGORIES:earnings\,US\,earnings\,GLP-1\,obesity\,pharma-guidance\,diabetes\,guidance
SEQUENCE:0
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:Review catalyst preview: Eli Lilly Q2 2026财报与GLP-1/代谢管线指引窗口
END:VALARM
BEGIN:VALARM
TRIGGER:PT24H
ACTION:DISPLAY
DESCRIPTION:Complete post-event review: Eli Lilly Q2 2026财报与GLP-1/代谢管线指引窗口
END:VALARM
END:VEVENT
END:VCALENDAR